Related Experiment Video
Updated: Dec 21, 2025

Subcutaneous Infection of Methicillin Resistant Staphylococcus Aureus MRSA
Published on: February 9, 2011
Twice- and Thrice-daily Cephalexin Dosing for Staphylococcus aureus Infections in Children
Amanda Gwee1,2,3, Julie Autmizguine4,5,6, Nigel Curtis1,2,3
1From the Department of Paediatrics, The University of Melbourne, Parkville, Victoria, Australia.
Background:
Cephalexin is used for the treatment of methicillin-susceptible Staphylococcus aureus (MSSA) infections in children. Although 4 times daily dosing is recommended, less frequent dosing regimens are often prescribed to improve treatment acceptability and adherence. We developed a population pharmacokinetic model of cephalexin in children to determine a twice-daily (BID) and thrice-daily (TID) cephalexin dosing regimen for MSSA infections.
Methods:
A population pharmacokinetic model was developed using a nonlinear mixed effects modeling approach. The dataset used was from a prospective open-label pharmacokinetic study of orally administered cephalexin in 12 children 1-16 years of age with bone and joint infections. Simulations were performed to determine a BID and TID dosing regimen so that ≥90% of children in this age group would achieve the pharmacodynamic target for MSSA (ie, time that the free drug concentration exceeds the minimum inhibitory concentration of the bacteria for at least 40% of the dosing interval).
Results:
The final model was 1 compartment with a transit compartment model to account for delay in oral absorption. For BID dosing, doses of 22-45 and 80 mg/kg were required for MSSA with minimum inhibitory concentrations of 1-2 and 4 mg/L, respectively. For TID dosing, the respective required doses were 15-25 and 45 mg/kg.
Conclusions:
Our study proposes a BID and TID cephalexin dosing regimen that can be prospectively evaluated. Through reducing the dose frequency of this widely prescribed antibiotic, we can reduce the medication burden for children and improve treatment compliance for MSSA infections.
Insights
This study developed new dosing schedules for cephalexin in children to treat Staphylococcus aureus infections. Twice-daily and thrice-daily regimens were identified to improve treatment adherence and reduce medication burden.
Area of Science:
- Pharmacokinetics and Pharmacodynamics
- Pediatric Infectious Diseases
- Antibiotic Dosing Optimization
Background:
- Cephalexin is a common antibiotic for methicillin-susceptible Staphylococcus aureus (MSSA) infections in children.
- Standard dosing (4 times daily) is often reduced to improve patient adherence.
- Population pharmacokinetics can inform optimized dosing strategies.
Purpose of the Study:
- To develop a population pharmacokinetic model for cephalexin in pediatric patients.
- To determine appropriate twice-daily (BID) and thrice-daily (TID) cephalexin dosing regimens for MSSA infections.
- To achieve pharmacodynamic targets for effective treatment in children.
Main Methods:
- Utilized a nonlinear mixed-effects modeling approach for population pharmacokinetics.
- Data from a prospective pharmacokinetic study in 12 children (1-16 years) with bone and joint infections.
- Simulations to identify BID and TID regimens ensuring ≥90% of children meet pharmacodynamic targets.
Main Results:
- A one-compartment model with a transit compartment for oral absorption delay was established.
- For BID dosing, required doses ranged from 22-45 mg/kg (MIC 1-2 mg/L) to 80 mg/kg (MIC 4 mg/L).
- For TID dosing, required doses ranged from 15-25 mg/kg (MIC 1-2 mg/L) to 45 mg/kg (MIC 4 mg/L).
Conclusions:
- Proposed BID and TID cephalexin dosing regimens for prospective evaluation.
- Reduced dosing frequency can decrease the medication burden for pediatric patients.
- Optimized dosing can enhance treatment compliance for MSSA infections in children.
Related Concept Videos
Pharmacokinetics in Pediatric Patients: Drug Excretion
Drug Dosing: Infants and Children
Dosage Interval and Administration Route: Determination Methods
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations
Dosage Regimen: Multiple Oral Dosage

